Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

- Subject was age 18 or older and in good health (Investigator discretion) with a recent stable medical history. - Subject had a clinical diagnosis of psoriasis for at least 6 months, had moderate to severe plaque psoriasis. - Subject was able and willing to self-administer sc injections or had available qualified person(s) to administer sc injections

- Subject had previously received anti-TNF therapy. - Subject cannot discontinue systemic therapies and/or topical therapies for the treatment of psoriasis and cannot avoid UVB or PUVA phototherapy - Subject cannot avoid excessive sun exposure - Subject is taking or requires oral or injectable corticosteroids - Subject considered by the investigator, for any reason, to be an unsuitable candidate for the study - Female subject who is pregnant or breast-feeding or considering becoming pregnant